Breast Cancer Screening: Risk, Mammograms, Dense Breasts, and High-Risk Plans

Screening means looking for cancer in a woman who has no symptoms. That is a different activity from evaluating a lump, and the two get confused constantly. Most of the confusion in public advice, though, comes from a real scientific disagreement about how often to screen and when to begin.

What the current recommendation says

On April 30, 2024, the U.S. Preventive Services Task Force issued a final recommendation that women be screened with mammography every other year beginning at age 40 and continuing through age 74. The Task Force graded this a B recommendation, meaning it found adequate evidence of moderate net benefit.

This was a change in position. The 2016 recommendation had supported biennial mammography for women aged 50 to 74 while treating screening between 40 and 49 as an individual decision. The 2024 statement replaced that individualized approach for women in their forties with a positive recommendation to screen.

Why the starting age moved

Two findings drove the change. First, invasive breast cancer is being diagnosed more often in younger women: incidence among women aged 40 to 49 rose by an average of 2.0% per year between 2015 and 2019, a faster rate of increase than in earlier periods. Second, the burden is not distributed evenly. Black women have a breast cancer death rate roughly 40% higher than White women despite similar self-reported rates of mammography, and that mortality gap is widest among women under 50.

The Task Force's modeling put a number on what earlier screening buys. Beginning biennial screening at 40 rather than 50 was estimated to avert about 1.8 additional breast cancer deaths per 1,000 Black women screened. That figure is a median across four independent models, which is worth knowing: it is a projection, not a measurement, and different models produced different estimates.

Where the guidelines still disagree

Three recommendations are quoted most often, and they differ in both the starting age and the interval. The Task Force recommends mammography every other year from 40 through 74, a B recommendation. The American Cancer Society recommends annual mammography from 45 through 54, treats ages 40 to 44 as an option to begin annual screening rather than a recommendation to do so, and moves to every other year from 55 with the option of continuing annually, for as long as a woman is in good health and would expect to live at least another ten years. The American College of Radiology recommends annual mammography from 40 for women at average risk, and separately recommends that every woman have a formal breast cancer risk assessment by age 25 so that those at higher risk can start earlier and with additional imaging.

So the honest summary is that a claim of settled consensus to screen every woman routinely from 40 would be wrong in both directions: the Society’s recommendation begins at 45 and offers 40, and the College’s begins at 40 but annually rather than biennially. What the three do share is that screening in the forties is now a reasonable and supported choice rather than an exception. The disagreement that remains is real. Annual screening finds somewhat more cancers earlier; it also produces more false-positive results, more callbacks, and more biopsies that turn out benign. Which trade-off is right depends on how much a given woman weighs each of those, and it is a legitimate question to raise directly with your clinician rather than a discrepancy to resolve online.

Dense breasts: what is and is not settled

Dense breast tissue both raises breast cancer risk and makes mammograms harder to read. Many women now receive a density notification with their result and reasonably ask what to do about it.

The Task Force examined that question and concluded that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening with breast ultrasound or MRI in women found to have dense breasts on an otherwise negative mammogram. That is an I statement, and it means something specific: not that supplemental imaging is useless, but that the trials needed to say whether it saves lives have not been done. Additional imaging in this situation is a judgment call made with a clinician who knows your full risk picture, not a settled standard.

After 74, and before 40

For women aged 75 and older the Task Force again concluded the evidence is insufficient. Screening in that age group becomes an individual decision that turns on overall health, life expectancy, and how a woman would want an early cancer handled if one were found.

Below 40, routine screening is not recommended for women at average risk. The important qualifier is average.

High risk is a different plan entirely

Average-risk recommendations do not apply to women with a known BRCA1 or BRCA2 variant or other high-risk inherited variant, a strong family history of breast or ovarian cancer, prior chest radiation, certain high-risk breast biopsy findings, or a formally calculated lifetime risk in the high range. These situations can call for earlier screening, MRI in addition to mammography, genetic counseling, or risk-reducing medication.

If a first-degree relative had breast cancer, particularly before menopause, that is the single most useful thing to bring to a preventive visit. It changes the arithmetic, and it changes it before age 40.

Screening does not replace evaluating a symptom

This is the point most worth carrying away. A new breast lump, a change in the skin of the breast, nipple inversion or discharge that is bloody or occurs without squeezing, or a persistent focal area of pain deserves evaluation when it appears. Not at the next scheduled mammogram, and not deferred because a recent mammogram was normal. Screening mammography is designed to find cancer in the absence of symptoms; it is not designed to rule out a cancer you can feel.

Questions to bring to a visit

• Based on my family history, am I at average risk or higher than average?
• Do you recommend annual or every-other-year mammography for me, and why that interval?
• Was my mammogram reported as dense, and does that change what you recommend?
• Should I have formal risk assessment or genetic counseling?
• What symptoms should bring me in before my next scheduled screening?

Main takeaway

Current U.S. Preventive Services Task Force guidance is mammography every other year from 40 through 74. Some organizations recommend annually from 40, and that remaining disagreement is real and reasonable rather than a sign that someone is wrong. Dense breasts and a meaningful family history both move you off the average-risk pathway, and any new breast symptom is evaluated on its own schedule.

Sources

• U.S. Preventive Services Task Force — Final Recommendation Statement: Breast Cancer Screening (April 30, 2024). Source of the biennial 40–74 B recommendation, the insufficient-evidence conclusions for ages 75+ and for supplemental imaging in dense breasts, the 2.0% annual incidence increase in ages 40–49, and the modeled 1.8 additional deaths averted per 1,000 Black women screened.
• Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024 — published recommendation statement.
• American Cancer Society — statement supporting the updated USPSTF breast cancer screening guidelines (April 30, 2024).

Provenance

• Basis: the Task Force recommendation, its grade, the two insufficient-evidence conclusions, the incidence and mortality figures and the modelled deaths-averted estimate are taken from the sources cited above.
• Route of retrieval: guideline text was obtained through search results rendering the Task Force and American Cancer Society pages, not by direct retrieval of each document. The linked addresses were surfaced by those results.
• Organisation positions: the American College of Radiology interval and its risk-assessment-by-25 position are taken from the College’s own published statement on the final Task Force recommendations; the American Cancer Society age bands and intervals from the Society’s own published screening guidance and its statement of 30 April 2024. Both were surfaced through search results rendering those pages rather than by direct retrieval of the documents.